Table 5.
Group | Baseline | Exposure | Exposure | Exposure | Follow-up | |
---|---|---|---|---|---|---|
Week 4 | Week 8 | Week 12 | Week 16 | |||
Body temperature | IP | 36.4 ± 0.4 | 36.4 ± 0.4 | 36.3 ± 0.5 | 36.4 ± 0.4 | 36.5 ± 0.3 |
VM | 36.5 ± 0.4 | 36.2 ± 0.5 | 36.3 ± 0.5 | 36.3 ± 0.3 | 36.4 ± 0.3 | |
PL | 36.3 ± 0.4 | 36.3 ± 0.3 | 36.4 ± 0.4 | 36.4 ± 0.3 | 36.5 ± 0.4 | |
Systolic blood pressure | IP | 120 ± 11 | 117 ± 11 | 114 ± 10 | 117 ± 11 | 112 ± 12 |
VM | 112 ± 10 | 114 ± 10 | 110 ± 11 | 111 ± 12 | 112 ± 13 | |
PL | 112 ± 13 | 110 ± 11 | 113 ± 9 | 111 ± 13 | 112 ± 13 | |
Heart rate | IP | 76 ± 11 | 72 ± 7 | 74 ± 9 | 71 ± 9 | 72 ± 11 |
VM | 71 ± 9 | 74 ± 11 | 70 ± 8 | 68 ± 8 | 66 ± 9 | |
PL | 74 ± 8 | 71 ± 9 | 72 ± 6 | 72 ± 9 | 74 ± 7 |
IP = Iscucin® Populi, VM = Viscum Mali e planta tota, PL = placebo.